The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters

An observational study

Daniele Fagnani, Alessandro Bertolini, Laura Catena, Maunzio Tomirotti, Marilena Visini, Adriano Alatri, Alberto De Paoli, Gian Marco Aondio, Massimo Milani, Guido Arpaia, Claudio Cimminiello

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Infections in cancer patients after implantation of a central venous device (CVD) are not infrequent and are potentially serious. The possibility of limiting this complication with antithrombotic drugs is still debated. For this observational study, we recorded the routine management of CVD in cancer patients in 18 oncology centers in Lombardy (northern Italy), assessing the effect of antithrombotic prophylaxis on catheter-related infections. Out of 1410 patients enrolled, 451 received antithrombotic prophylaxis continuously after implantation of the central line. During a median follow-up of 30 months, 57 catheter-related infections were reported in the 1390 patients seen at least once at follow-up visits (4.1 % of the whole series), giving an overall incidence of 0.10 infections per 1000 catheter days. This complication was significantly more frequent among patients with an indwelling central venous catheter, or peripherally inserted catheter, than among those with a port device, and the group not given antithrombotic prophylaxis had 0.14 infective complications/1000 CVD days compared with 0.05/1000 CVD days (odds ratio 2.4; 95% confidence interval 1.7-5.0) for those treated. Antithrombotic prophylaxis protected against infections at the catheter exit site and track but not against systemic infections. Confirming earlier evidence, this study found a reduction in catheter-related infections in patients given antithrombotic prophylaxis. However, this reduction, reflecting local infections, seems unlikely to be one of the mechanisms explaining the lower mortality among our patients treated with anticoagulants. Blood Coagul Fibrinolysis 20:35-40

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalBlood Coagulation and Fibrinolysis
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Central Venous Catheters
Observational Studies
Catheter-Related Infections
Equipment and Supplies
Neoplasms
Infection
Catheters
Indwelling Catheters
Fibrinolysis
Anticoagulants
Italy
Odds Ratio
Confidence Intervals
Mortality
Incidence
Pharmaceutical Preparations

Keywords

  • Antithrombotic prophylaxis
  • Cancer
  • Catheter-related infections
  • Central venous catheters
  • Low-dose warfarin
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters : An observational study. / Fagnani, Daniele; Bertolini, Alessandro; Catena, Laura; Tomirotti, Maunzio; Visini, Marilena; Alatri, Adriano; De Paoli, Alberto; Aondio, Gian Marco; Milani, Massimo; Arpaia, Guido; Cimminiello, Claudio.

In: Blood Coagulation and Fibrinolysis, Vol. 20, No. 1, 01.2009, p. 35-40.

Research output: Contribution to journalArticle

Fagnani, D, Bertolini, A, Catena, L, Tomirotti, M, Visini, M, Alatri, A, De Paoli, A, Aondio, GM, Milani, M, Arpaia, G & Cimminiello, C 2009, 'The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: An observational study', Blood Coagulation and Fibrinolysis, vol. 20, no. 1, pp. 35-40. https://doi.org/10.1097/MBC.0b013e32831bc2f8
Fagnani, Daniele ; Bertolini, Alessandro ; Catena, Laura ; Tomirotti, Maunzio ; Visini, Marilena ; Alatri, Adriano ; De Paoli, Alberto ; Aondio, Gian Marco ; Milani, Massimo ; Arpaia, Guido ; Cimminiello, Claudio. / The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters : An observational study. In: Blood Coagulation and Fibrinolysis. 2009 ; Vol. 20, No. 1. pp. 35-40.
@article{172715ecf6cf445bb08199698aa6b1d1,
title = "The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: An observational study",
abstract = "Infections in cancer patients after implantation of a central venous device (CVD) are not infrequent and are potentially serious. The possibility of limiting this complication with antithrombotic drugs is still debated. For this observational study, we recorded the routine management of CVD in cancer patients in 18 oncology centers in Lombardy (northern Italy), assessing the effect of antithrombotic prophylaxis on catheter-related infections. Out of 1410 patients enrolled, 451 received antithrombotic prophylaxis continuously after implantation of the central line. During a median follow-up of 30 months, 57 catheter-related infections were reported in the 1390 patients seen at least once at follow-up visits (4.1 {\%} of the whole series), giving an overall incidence of 0.10 infections per 1000 catheter days. This complication was significantly more frequent among patients with an indwelling central venous catheter, or peripherally inserted catheter, than among those with a port device, and the group not given antithrombotic prophylaxis had 0.14 infective complications/1000 CVD days compared with 0.05/1000 CVD days (odds ratio 2.4; 95{\%} confidence interval 1.7-5.0) for those treated. Antithrombotic prophylaxis protected against infections at the catheter exit site and track but not against systemic infections. Confirming earlier evidence, this study found a reduction in catheter-related infections in patients given antithrombotic prophylaxis. However, this reduction, reflecting local infections, seems unlikely to be one of the mechanisms explaining the lower mortality among our patients treated with anticoagulants. Blood Coagul Fibrinolysis 20:35-40",
keywords = "Antithrombotic prophylaxis, Cancer, Catheter-related infections, Central venous catheters, Low-dose warfarin, Venous thromboembolism",
author = "Daniele Fagnani and Alessandro Bertolini and Laura Catena and Maunzio Tomirotti and Marilena Visini and Adriano Alatri and {De Paoli}, Alberto and Aondio, {Gian Marco} and Massimo Milani and Guido Arpaia and Claudio Cimminiello",
year = "2009",
month = "1",
doi = "10.1097/MBC.0b013e32831bc2f8",
language = "English",
volume = "20",
pages = "35--40",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters

T2 - An observational study

AU - Fagnani, Daniele

AU - Bertolini, Alessandro

AU - Catena, Laura

AU - Tomirotti, Maunzio

AU - Visini, Marilena

AU - Alatri, Adriano

AU - De Paoli, Alberto

AU - Aondio, Gian Marco

AU - Milani, Massimo

AU - Arpaia, Guido

AU - Cimminiello, Claudio

PY - 2009/1

Y1 - 2009/1

N2 - Infections in cancer patients after implantation of a central venous device (CVD) are not infrequent and are potentially serious. The possibility of limiting this complication with antithrombotic drugs is still debated. For this observational study, we recorded the routine management of CVD in cancer patients in 18 oncology centers in Lombardy (northern Italy), assessing the effect of antithrombotic prophylaxis on catheter-related infections. Out of 1410 patients enrolled, 451 received antithrombotic prophylaxis continuously after implantation of the central line. During a median follow-up of 30 months, 57 catheter-related infections were reported in the 1390 patients seen at least once at follow-up visits (4.1 % of the whole series), giving an overall incidence of 0.10 infections per 1000 catheter days. This complication was significantly more frequent among patients with an indwelling central venous catheter, or peripherally inserted catheter, than among those with a port device, and the group not given antithrombotic prophylaxis had 0.14 infective complications/1000 CVD days compared with 0.05/1000 CVD days (odds ratio 2.4; 95% confidence interval 1.7-5.0) for those treated. Antithrombotic prophylaxis protected against infections at the catheter exit site and track but not against systemic infections. Confirming earlier evidence, this study found a reduction in catheter-related infections in patients given antithrombotic prophylaxis. However, this reduction, reflecting local infections, seems unlikely to be one of the mechanisms explaining the lower mortality among our patients treated with anticoagulants. Blood Coagul Fibrinolysis 20:35-40

AB - Infections in cancer patients after implantation of a central venous device (CVD) are not infrequent and are potentially serious. The possibility of limiting this complication with antithrombotic drugs is still debated. For this observational study, we recorded the routine management of CVD in cancer patients in 18 oncology centers in Lombardy (northern Italy), assessing the effect of antithrombotic prophylaxis on catheter-related infections. Out of 1410 patients enrolled, 451 received antithrombotic prophylaxis continuously after implantation of the central line. During a median follow-up of 30 months, 57 catheter-related infections were reported in the 1390 patients seen at least once at follow-up visits (4.1 % of the whole series), giving an overall incidence of 0.10 infections per 1000 catheter days. This complication was significantly more frequent among patients with an indwelling central venous catheter, or peripherally inserted catheter, than among those with a port device, and the group not given antithrombotic prophylaxis had 0.14 infective complications/1000 CVD days compared with 0.05/1000 CVD days (odds ratio 2.4; 95% confidence interval 1.7-5.0) for those treated. Antithrombotic prophylaxis protected against infections at the catheter exit site and track but not against systemic infections. Confirming earlier evidence, this study found a reduction in catheter-related infections in patients given antithrombotic prophylaxis. However, this reduction, reflecting local infections, seems unlikely to be one of the mechanisms explaining the lower mortality among our patients treated with anticoagulants. Blood Coagul Fibrinolysis 20:35-40

KW - Antithrombotic prophylaxis

KW - Cancer

KW - Catheter-related infections

KW - Central venous catheters

KW - Low-dose warfarin

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=58849105363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849105363&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e32831bc2f8

DO - 10.1097/MBC.0b013e32831bc2f8

M3 - Article

VL - 20

SP - 35

EP - 40

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 1

ER -